| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 93.97 | 59.6% | 102.3% |
| Total Income | 93.97 | 59.6% | 102.3% |
| Expenditure | 83.68 | 0.3% | 5.8% |
| PBT | — | ||
| Net Profit | 9.55 | 137.3% | 129.8% |
| OPM | 10.95% | 53.47pp | 81.23pp |
| NPM | 10.16% | 53.66pp | 79.22pp |
| EPS | 0.06 | 135.3% | 127.3% |
Adaptive Biotechnologies Reports Q3 2025 Revenue Up 102% to $94.0 Million
04 May 2026 · 4 May, 7:59 am
Summary
Adaptive Biotechnologies reported a strong third quarter in 2025, with revenue reaching $94.0 million, representing a 102% increase year-over-year. The MRD business was a key driver, achieving both profitability and cash flow positivity. The company is raising its full year 2025 MRD revenue guidance to $202 million to $207 million, reflecting annual growth of 39% to 42%. Net income for the quarter was $9.5 million, a significant improvement from the net loss of $32.1 million in the same period last year.
Key Highlights
- 1
Adaptive Biotechnologies reported revenue of $94.0 million for the third quarter of 2025, a 102% increase year-over-year.
- 2
The MRD business grew 52% compared to the third quarter of 2024, contributing 60% of total revenue.
- 3
The MRD business achieved cash flow positivity in the third quarter of 2025 with Adjusted EBITDA of $7.0 million.
- 4
clonoSEQ test volume grew 38% to 27,111 tests delivered in the third quarter of 2025 compared to the same period in 2024.
- 5
The company is raising full year 2025 MRD revenue guidance to a new range of $202 million to $207 million, implying annual growth of 39% to 42%.
- 6
Net income was $9.5 million for the third quarter of 2025, compared to a net loss of $32.1 million for the same period in 2024.
Management Comments
Chad Robins
“Our third quarter results reflect another period of strong growth and financial progress. Our MRD business has reached a major inflection point, having achieved both profitability and cash flow positivity, driven by disciplined execution and accelerating adoption of clonoSEQ. With strong momentum in MRD and good progress in our Immune Medicine programs, we’re well positioned for sustained growth and long-term value creation.”
Informational and educational content only. Not investment advice.